Please provide your email address to receive an email when new articles are posted on . Baricitinib is FDA-approved as the first and only treatment of severe alopecia areata in adults. Baricitinib is ...
Alopecia areata is an autoimmune condition characterized by rapid hair loss in the scalp, eyebrows, and eyelashes, for which treatments are limited. Baricitinib, an oral, selective, reversible ...
Please provide your email address to receive an email when new articles are posted on . Within the baricitinib group, patients experienced a mean Vitiligo Area Scoring Index score change of 44.8% from ...
The effects of the JAK inhibitor baricitinib (Olumiant) waned after treatment was stopped among patients with new-onset type 1 diabetes, 2-year data from the phase II BANDIT trial showed. After ...
Data from two separate phase 2 trials presented at the annual meeting of the European Academy of Dermatology and Venereology suggest that two more Janus kinase (JAK) inhibitors are showing promise for ...
In 2023, the groundbreaking Australian BANDIT (Baricitinib in New Onset Type 1 Diabetes) trial [1] reported that a daily pill of baricitinib, commonly prescribed for rheumatoid arthritis and alopecia, ...
Baricitinib demonstrated significant efficacy in severe alopecia areata, with over 50% achieving substantial hair regrowth within a year. Early intervention and patient selection, particularly those ...
Baricitinib can effectively treat polymyalgia rheumatica (PMR) without the use of oral glucocorticoids, according to results from a small, randomized, double-blind, placebo-controlled study. Among the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results